October 8, 2010 – Siemens PETNET Solutions has expanded its imaging biomarker capabilities in Nottingham, England and can now produce new biomarkers as investigational medicine products (IMP) in the United Kingdom.
The IMPs include a hypoxic agent that can identify tumor tissues with low oxygen supply and an amyloid agent for PET imaging of ß-amyloid deposits in the brain.
For more information: www.siemens.com/healthcare
The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...
April 07, 2026 
March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...
April 06, 2026 
March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S ...
March 24, 2026 
March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...
March 17, 2026 
Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ...
February 26, 2026 
Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...
February 03, 2026 
Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...
January 27, 2026 
Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...
November 12, 2025 
Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...
October 03, 2025 
Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...
September 18, 2025 